The FDA declared the semaglutide shortage resolved in February 2025, with 503A compounding winding down around April 22, 2025 and 503B around May 22, 2025
Nausea leads the list, followed by diarrhea, constipation, and occasionally vomiting
Coverage varies widely by plan
The relationship between TIMP-2 and GSH in the ACC seemed marginally group dependent ( = 0.784, p =0.051, see Figure 4), where the relationship was positive in PTSD participants but negative among HC participants
These reactions often present as persistent redness, swelling, and dry, flaky skin around the eyes, potentially triggered by the bodys inflammatory response or rapid metabolic changes